One To Watch

Atavistik Bio

A clinical-stage biotechnology company developing small-molecule medicines that target previously inaccessible regulatory sites on disease-related proteins. Atavistik Bio focuses on precision allosteric therapeutics designed to modulate protein function with high selectivity and improved tolerability.

Company Overview

Atavistik Bio develops small-molecule therapeutics based on allosteric modulation, a strategy that targets regulatory pockets on proteins rather than the conventional active site. This approach aims to enable more selective control of protein function and potentially reduce off-target effects.

The company applies its discovery platform to genetically validated disease targets, with programs focused primarily on oncology and rare diseases where precision targeting may provide disease-modifying benefit.

Headquarters and Global Presence

Atavistik Bio is headquartered in Cambridge, Massachusetts, United States.

The company operates as a research-focused biotechnology organization, conducting preclinical and clinical development through collaborations with academic institutions and industry partners.

Founding and History

Atavistik Bio was founded in 2021 to develop medicines that exploit allosteric regulation of proteins, an emerging area of drug discovery.

Since its launch the company has raised significant venture funding to advance its platform and pipeline. A Series B financing announced in 2025 raised $120 million, later extended in 2026 to approximately $160 million to support clinical development of its lead programs.

The company’s leadership team includes experienced drug-discovery scientists and executives from established pharmaceutical and biotechnology companies.

Therapy Areas and Focus

Atavistik Bio’s research programs target diseases where selective modulation of protein activity may provide therapeutic benefit.

Key areas include:

Rare vascular diseases such as hereditary hemorrhagic telangiectasia (HHT)
Hematologic malignancies including myeloproliferative neoplasms (MPNs)
Oncology and other genetically defined diseases

These indications involve molecular pathways where mutation-specific targeting may offer advantages over broader inhibitors.

Technology Platforms and Modalities

The company’s core technology is its AMPS platform, a discovery system designed to identify and exploit allosteric binding sites on proteins.

Key modalities include:

Allosteric small-molecule inhibitors
Mutation-selective kinase inhibitors
Structure-guided drug design targeting regulatory protein pockets

Allosteric drugs bind to regulatory sites on proteins rather than the catalytic active site, potentially enabling higher specificity and improved safety profiles.

Key Pipeline Programs

Selected programs include:

ATV-1601, an oral allosteric AKT1-selective inhibitor being developed for hereditary hemorrhagic telangiectasia (HHT).
A JAK2 V617F mutant-selective inhibitor program targeting myeloproliferative neoplasms (MPNs).

Additional discovery programs are being developed across oncology and rare disease targets.

Key Personnel

Bryan Stuart, Chief Executive Officer

Strategic Partnerships and Investors

Atavistik Bio has attracted venture financing from several biotechnology-focused investors.

Key investors include:

The Column Group
Nextech Invest
Lux Capital
Regeneron Ventures
RA Capital Management

The company has also established research collaborations with pharmaceutical partners to accelerate discovery of new allosteric therapeutics.

FAQ Section

The company focuses on allosteric modulation, targeting regulatory pockets on proteins rather than the active catalytic site. These allosteric sites can control protein activity indirectly, allowing drug designers to fine-tune biological pathways.

This approach may enable therapies that are more selective and less disruptive to normal cellular function than conventional inhibitors.

Many traditional drugs bind to the active site of enzymes or receptors, which can lead to limited selectivity because these sites are often conserved across related proteins.

Allosteric sites tend to be more structurally unique, creating opportunities to design drugs that selectively modulate a specific protein or mutation.

Atavistik’s lead programs focus on rare and genetically defined diseases including hereditary hemorrhagic telangiectasia and myeloproliferative neoplasms.

Both conditions involve molecular pathways that may benefit from mutation-specific inhibition rather than broader pathway blockade.

Current JAK inhibitors often suppress both mutant and normal forms of the enzyme, which can interfere with normal blood cell production.

A mutant-selective inhibitor could potentially suppress cancer-driving signaling while preserving healthy bone marrow function.

Atavistik Bio is transitioning from discovery to early clinical development. Its AKT1-selective inhibitor program for hereditary hemorrhagic telangiectasia is expected to enter clinical testing around 2026.

The company has raised multiple venture financing rounds since its launch, including a Series B round totaling approximately $160 million that supports advancement of its pipeline through early clinical development.

Key developments include: